v3.26.1
Summary of Significant Accounting Policies and Other Information (Tables)
 3 Months Ended
Mar. 31, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedules of Concentration of Risk, by Risk Factor
The following table presents customers individually accounting for more than 10% of the Company’s net sales:
For the Three Months Ended March 31,
20262025
Customer B12 %22 %
Customer C27 %10 %
Customer E**12 %
The following table presents customers individually accounting for more than 10% of the Company’s trade accounts receivable:
As of March 31, 2026As of December 31, 2025
Customer B10 %14 %
Customer C16 %10 %
Customer E**11 %
Customer G11 %11 %
The following table presents suppliers individually accounting for more than 10% of the Company’s purchases:
For the Three Months Ended March 31,
20262025
Supplier A10 %19 %
**Less than 10% of the total
Schedule of Inventory and Activity in Inventory Allowance
Inventories consist of the following:
(in thousands)

Inventories
As of March 31, 2026As of December 31, 2025
Raw materials $108,983 $105,225 
Work in process3,665 5,103 
Finished goods25,253 25,288 
Total inventories137,901 135,616 
Inventory allowance(8,658)(8,253)
Inventories, net$129,243 $127,363 
Activity in the Company’s inventory allowance was as follows:
(in thousands)For the Three Months Ended March 31,
Inventory Allowance20262025
Balance at beginning of period$8,253 $8,135 
Charged to expense527 237 
Write-offs(122)(31)
Balance at end of period$8,658 $8,341 
Schedule of Other Accrued Liabilities
Other accrued liabilities consisted of the following:
(in thousands)

Other Accrued Liabilities
As of March 31, 2026As of December 31, 2025
Accrued product warranty$6,319 $6,634 
Accrued litigation 1
1,547 1,400 
Contract liabilities2,597 3,486 
Accrued compensation and benefits9,171 19,565 
Accrued interest expense254 268 
Stock appreciation rights liability 2
1,554 1,070 
Non-interest bearing note payable753 740 
Customs accrual1,965 1,248 
Taxes payable730 257 
Other3,420 2,685 
Total$28,310 $37,353 
1 As of March 31, 2026 and December 31, 2025 accrued litigation includes accruals related to various ongoing legal matters including associated legal fees. See Note 11. Commitments and Contingencies for further information regarding the various ongoing legal matters.
2 The Company has an incentive compensation plan, which authorizes the granting of a variety of different types of awards including, but not limited to, non-qualified stock options, incentive stock options, Stock Appreciation Rights (“SARs”), Restricted Stock Awards (“RSAs”), deferred stock and performance units to its executive officers, employees, consultants and Directors. The SAR awards granted for the year ended March 31, 2026 and December 31, 2025 were all liability classified awards and remained outstanding. See Note 14. Stock-Based Compensation in the Company’s 2025 Annual Report for additional information on the SARs and RSAs.
Schedule of Accrued Product Warranty Activities
Accrued product warranty activities included in Other noncurrent liabilities on the Consolidated Balance Sheet are presented below:
(in thousands)For the Three Months Ended March 31,
Accrued Product Warranty20262025
Balance at beginning of period$8,193 $13,972 
Current period provision *
675 993 
Changes in estimates for preexisting warranties **
(50)(282)
Payments made during the period(1,359)(3,287)
Balance at end of period7,459 11,396 
Less: current portion6,319 8,375 
Noncurrent accrued product warranty
(included with Other Noncurrent liabilities)		$1,140 $3,021 
*Warranty costs, net of supplier recoveries and other adjustments, were $0.6 million for both the three months ended March 31, 2026 and 2025. Supplier recoveries were $0.0 million and $0.1 million for the three months ended March 31, 2026 and 2025, respectively.
**Changes in estimates for preexisting warranties reflect changes in the Company’s estimate of warranty costs for products sold in prior periods. Such adjustments typically occur when claims experience deviates from historical and expected trends. During the three months ended March 31, 2026, the Company recorded a benefit for changes in estimates of preexisting warranties of $0.1 million, or $0.00 per diluted share. During the three months ended March 31, 2025, the Company recorded a benefit for changes in estimates of preexisting warranties $0.3 million, or $0.01 per diluted share.